• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Owens & Minor Announces Upsize and Pricing of Senior Secured Notes Offering

    4/2/25 5:28:00 PM ET
    $OMI
    Medical Specialities
    Health Care
    Get the next $OMI alert in real time by email

    Owens & Minor, Inc. (NYSE:OMI) (the "Company") announced today the upsize and pricing of its private offering (the "Offering") of $1 billion aggregate principal amount of its 10.000% senior secured notes due 2030 (the "Notes"). The Offering is expected to close on April 4, 2025, subject to customary closing conditions. The Notes will bear interest at the rate of 10.000% per year. The Notes will mature on April 15, 2030 (subject to certain earlier maturity triggers). The Notes were offered at a price of 100% of their principal amount.

    Unless the previously announced acquisition (the "Acquisition") of Rotech Healthcare Holdings Inc. ("Rotech") is consummated substantially concurrently with the closing of the Offering, the Company will deposit the gross proceeds from the Offering into a segregated escrow account until the date that the Acquisition has been consummated. The consummation of the Acquisition is subject to customary closing conditions.

    The Notes will be fully and unconditionally guaranteed, jointly and severally, on a senior secured basis by the Company and certain domestic subsidiaries of the Company that guarantee the Company's existing term loan facility and revolving credit facility. If the issue date occurs prior to the closing of the Acquisition (and subject to applicable grace periods), the Notes will be secured only by a first-priority security interest in the escrow account and all funds on deposit therein. Following the completion of the Acquisition, the Notes and related guarantees will be secured on a first-priority basis by liens on the same assets that secure the Company's existing term loan facility and revolving credit facility.

    Upon the closing of the Offering or, if applicable, upon consummation of the Acquisition, the Company intends to use the net proceeds of the Offering, together with cash on hand and expected borrowings under a new senior secured incremental term loan B facility to finance the consummation of the Acquisition and the other transactions contemplated by the merger agreement, including the repayment of Rotech debt and to pay Acquisition related fees and expenses. Any remaining net proceeds will be used for working capital and general corporate purposes.

    The Notes have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States, or for the benefit of U.S. persons, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities or blue sky laws. Accordingly, the Notes were offered only to persons reasonably believed to be "qualified institutional buyers," as that term is defined under Rule 144A of the Securities Act, or outside the United States to non-"U.S. persons" in accordance with Regulation S under the Securities Act.

    A confidential offering memorandum for the Offering has been made available to such eligible persons. The Offering is being conducted in accordance with the terms and subject to the conditions set forth in such confidential offering memorandum.

    This press release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, or solicitation to buy, if at all, will be made only by means of a confidential offering memorandum. The Offering is not conditioned on the consummation of the Acquisition, which, if consummated, may occur subsequent to the closing of the Offering. This press release does not constitute a notice of repayment of any outstanding indebtedness of Rotech. The terms and conditions of the incremental term loan B facility have not been finalized and are therefore subject to change. The completion of the Offering is not conditioned upon our entering into the incremental term loan B facility, and our entering into such facility is not conditioned upon completion of the Offering.

    About Owens & Minor

    Owens & Minor, Inc. (NYSE:OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™.

    * Registered Trademark or Trademark of O&M Halyard or its affiliates.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company's expectations regarding the proposed Acquisition and the future performance and financial results of the Company's business and other non-historical statements. Some of these statements can be identified by terms and phrases such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words, including statements relating to the Acquisition, the Offering and the related financing for the Acquisition. The Company cautions readers of this communication that such "forward looking statements," wherever they occur in this press release or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company's senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the "forward-looking statements."

    Factors that could cause the Company's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; the inability to complete the proposed Acquisition due to the failure to satisfy other conditions to completion of the proposed Acquisition, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed Acquisition; risks related to disruption of management's attention from the Company's ongoing business operations due to the proposed Acquisition; the effect of the announcement of the proposed Acquisition on the Company's relationships with its customers, suppliers and other third parties, as well as its operating results and business generally; the risk that the proposed Acquisition will not be consummated in a timely manner; exceeding the expected costs of the proposed Acquisition; the risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected; and the risk that the combined company may be unable to achieve expected synergies or that it may take longer than expected to achieve those synergies.

    Additional factors that could cause the Company's actual outcomes or results to differ materially from those described in these forward-looking statements can be found in the "Risk Factors" sections of the Company's most recent Annual Report on Form 10-K for the period ended December 31, 2024, as such factors may be further updated from time to time in the Company's other filings with the U.S. Securities and Exchange Commission (the "SEC"). These reports are or will be accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements included in this press release and in the Company's filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    OMI-CORP

    OMI-IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250402267148/en/

    Media contact

    Stacy Law

    [email protected]

    Get the next $OMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMI

    DatePrice TargetRatingAnalyst
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    2/26/2024$24.00Market Perform
    Leerink Partners
    1/3/2024$21.00Equal Weight
    Barclays
    10/13/2022$52.00 → $18.00Buy → Neutral
    Citigroup
    10/12/2022$43.00 → $17.00Buy → Underperform
    BofA Securities
    10/12/2022$62.00 → $22.00Outperform → Neutral
    Robert W. Baird
    4/26/2022$55.00Buy
    Citigroup
    4/1/2022$43.00Neutral
    Credit Suisse
    More analyst ratings

    $OMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Owens & Minor upgraded by Citigroup with a new price target

      Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously

      7/19/24 7:41:01 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Owens & Minor with a new price target

      Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00

      2/26/24 8:10:20 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Owens & Minor with a new price target

      Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00

      1/3/24 8:05:34 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Coliseum Capital Management, Llc bought $3,073,750 worth of shares (410,000 units at $7.50) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/10/25 9:43:55 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $4,291,218 worth of shares (528,356 units at $8.12) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/7/25 8:21:15 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $27,386,158 worth of shares (2,893,412 units at $9.47) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      3/4/25 9:07:16 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rollins Carissa was granted 28,914 shares, increasing direct ownership by 116% to 53,902 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:11:21 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Kline Teresa L. was granted 28,914 shares, increasing direct ownership by 115% to 54,125 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:10:49 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Henkel Robert J was granted 28,914 shares, increasing direct ownership by 60% to 77,412 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:10:08 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Leadership Updates

    Live Leadership Updates

    See more
    • Owens & Minor Names Tammy Gomez EVP and Chief Human Resources Officer

      Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect

      6/22/22 6:50:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces Major Innovations to Products & Healthcare Services Network

      Transformative investments in technology, automation and analytics capabilities will help improve supply chain visibility and resiliency for Products & Healthcare Services customers and lay the foundation for future innovations Owens & Minor, Inc. (NYSE:OMI) today announced important milestones in advancing the medical distribution capabilities of its Products & Healthcare Services (P&HS) business segment, which provides essential products and services to thousands of healthcare customers. These milestones are the result of recent company investments in new technology, automation and analytics capabilities geared specifically toward driving greater efficiencies for the P&HS segment and imp

      4/9/25 4:30:00 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Financials

    Live finance-specific insights

    See more
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Reports Fourth Quarter & Full Year Financial Results and Announces Sale Process Underway for Products & Healthcare Services Segment

      Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod

      2/28/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    SEC Filings

    See more
    • Owens & Minor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/16/25 8:30:34 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Owens & Minor Inc.

      10-Q - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/8/25 4:05:35 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/8/25 6:35:09 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      11/12/24 10:32:12 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/13/24 5:12:07 PM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/12/24 5:29:41 PM ET
      $OMI
      Medical Specialities
      Health Care